Grant: Engage Grants Program
Queen's University
$25,000.00
Oxygen-17 NMR Studies of Binding of Homotaurine to Amyloid beta Peptides
EF 2011-12
Résumé
This engage grant is requested to foster a new research partnership between Bellus Health Inc. and the research
laboratory of Professor Gang Wu at Queen's University. Bellus Health Inc. is a leading Canadian
biopharmaceutical company specialized in the development of therapeutics for the treatment of amyloid-related
diseases such as Alzheimer's disease. Recently, Bellus Health has successfully lunched in the market a
homotaurin-based nutraceutical product, VivimindTM, for brain (hippocampus) protection. To help better
understand the mechanism of action, Prof. Wu proposes to use a new nuclear magnetic resonance (NMR)
spectroscopic technique developed in his laboratory to study the interaction between homotaurine and amyloid
beta peptides (a key component of the physipathology of Alzheimer's disease). This new NMR technique is
based on detection of oxygen element rather than the commonly used hydrogen, carbon, and nitrogen elements.
This new oxygen NMR methodology is ideally suited for studying homotaurine and its binding properties, as
the active part of homotaurine is an oxygen-containing functional group. It is anticipated that this new research
partnership between Bellus Health and Prof. Wu's research group will provide a new angle to this very
challenging problem. The research outcomes will provide new insights into the interaction between drug
molecules and amyloid beta peptides and thus may generate new directions for the design of other drugs for
treating Alzheimer's disease.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
417875-2011
Name nom
Wu, Gang
Department département
Chemistry
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3404
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Biophysical chemistry
Research subject fr
Chimie biophysique
Partie
1
Nb partie
1
Application title
Oxygen-17 NMR Studies of Binding of Homotaurine to Amyloid beta Peptides
Keyword
NSERC
Application summary
This engage grant is requested to foster a new research partnership between Bellus Health Inc. and the research
laboratory of Professor Gang Wu at Queen's University. Bellus Health Inc. is a leading Canadian
biopharmaceutical company specialized in the development of therapeutics for the treatment of amyloid-related
diseases such as Alzheimer's disease. Recently, Bellus Health has successfully lunched in the market a
homotaurin-based nutraceutical product, VivimindTM, for brain (hippocampus) protection. To help better
understand the mechanism of action, Prof. Wu proposes to use a new nuclear magnetic resonance (NMR)
spectroscopic technique developed in his laboratory to study the interaction between homotaurine and amyloid
beta peptides (a key component of the physipathology of Alzheimer's disease). This new NMR technique is
based on detection of oxygen element rather than the commonly used hydrogen, carbon, and nitrogen elements.
This new oxygen NMR methodology is ideally suited for studying homotaurine and its binding properties, as
the active part of homotaurine is an oxygen-containing functional group. It is anticipated that this new research
partnership between Bellus Health and Prof. Wu's research group will provide a new angle to this very
challenging problem. The research outcomes will provide new insights into the interaction between drug
molecules and amyloid beta peptides and thus may generate new directions for the design of other drugs for
treating Alzheimer's disease.